Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

APPOINTMENT OF GENERAL MANAGER

The board (the "**Board**") of directors (the "**Director(s)**") of Xuanzhu Biopharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that having been recommended by the nomination committee of the Company, Ms. Xu Yanjun (徐艷君) ("**Ms. Xu**") has been appointed as the general manager of the Company with effect from January 5, 2026.

The term of office of Ms. Xu as the general manager of the Company commences from January 5, 2026, for a period of three years. Ms. Xu has entered into a service contract as an executive Director with the Company for a term of no more than three years from September 5, 2025. Ms. Xu will not receive additional remuneration in her capacity as the general manager of the Company.

According to code provision C.2.1 of the Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the roles of chairperson of the Board and chief executive officer shall be separate and shall not be performed by the same individual at the same time. Ms. Xu has been the chairperson of the Board and responsible for the overall management of the Company for more than five years and is a seasoned industry player with extensive experience in the industry and corporate management. In view of Ms. Xu's experience, personal qualifications and position in the Company, the Board considers that her service as the general manager of the Company will be conducive to ensuring the Company's consistent leadership and more efficient implementation of the Company's overall strategic plan.

The Board believes that this structure will not impair the balance of power and authority between the Board and the management of the Company, given that: (i) any decision to be made by the Board requires approval by at least a majority of the Directors; (ii) Ms. Xu and the other Directors are aware of and undertake to fulfil their fiduciary duties as Directors, which require, among other things, that they act for the benefits and in the best interests of the Company and will make decisions for the Company accordingly; and (iii) the balance of power and authority is ensured by the operations of the Board which comprises experienced and high caliber individuals who meet regularly to discuss issues affecting the operations of the Company. Moreover, the overall strategic and other key business, financial, and operational policies of the Company are made collectively after thorough discussions by both the Board and senior management. The Board will continue to review and consider splitting the roles of the chairperson of the Board and the general manager at a time when it is appropriate and suitable by taking into account the circumstances of the Group as a whole.

As of the date of this announcement, Ms. Xu holds 4,714,400 H Shares of the Company and is deemed to be interested in 8,466,510 H Shares held by Beihai Jixin Xuanzhu Investment Partnership (Limited Partnership) (北海吉鑫軒竹投資合夥企業(有限合夥)) by virtue of Part XV of the Securities and Futures Ordinance ("**SFO**"). Save as disclosed herein, Ms. Xu does not have any other interest in the shares or underlying shares of the Company within the meaning of Part XV of the SFO. She has not been subject to any public sanction by any statutory or regulatory authority.

Save as disclosed above, as at the date of this announcement, Ms. Xu (i) has not held any directorship in any publicly listed companies, whether in Hong Kong or overseas, in the past three years; (ii) does not have any relationship with any director, senior management, substantial or controlling shareholder (as defined in the Listing Rules) of the Company; and (iii) does not hold any other positions with the Company and other members of the Group or any other major appointments and professional qualifications. There is no other matter relating to the appointment of Ms. Xu as the general manager that needs to be brought to the attention of the shareholders of the Company, and there is no other matter which is required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules.

The biographical details of Ms. Xu are set out below:

Ms. Xu Yanjun (徐艷君), aged 53, is the chairperson of the Board and the executive Director. She was appointed as the Director and the chairperson of the Board in May 2020 and was then re-designated as the executive Director in November 2024. She began her career as a manager of the Production Department at Harbin Sequel Biological Engineering Pharmaceutical Co., Ltd. (哈爾濱世亨生物工程藥業股份有限公司) (currently known as Harbin Pacifico Biopharmaceutical Co., Ltd. (哈爾濱派斯菲科生物製藥有限公司)), where she was primarily responsible for manufacturing and R&D of blood products, from August 1995 to March 2003. Ms. Xu later joined Changchun Gaoxin BCHT Pharmaceutical Research Institute Co., Ltd. (長春高新百克藥物研究院有限公司) (currently known as Changchun BCHT Biotechnology Co. (長春百克生物科技股份公司)), the shares of which are listed on the Shanghai Stock Exchange STAR Market (stock code: 688276) in April 2003, and left in February 2019 with her last position as the deputy general manager.

Ms. Xu subsequently assumed several managerial and leadership roles within Sihuan Group, including: (i) the chairperson at Jilin Huikang Pharmaceutical Co., Ltd. (吉林匯康製藥有限公司) from January 2019 to June 2020; (ii) the chief project officer and director of the operation management center at Sihuan Pharm from February 2019 to May 2020; and (iii) a director at both Jilin Sihuan Pharmaceutical Co., Ltd. (吉林四環製藥有限公司) and Jilin Zhenao Pharmaceutical Co., Ltd. (吉林振澳製藥有限公司) from November 2019 to August 2020. Since July 2020, Ms. Xu has also served as a director and the general manager of Shijiazhuang Pusheng Pharmaceutical Technology Co., Ltd. (石家莊普晟醫藥科技有限公司).

Ms. Xu graduated from Heilongjiang College of Chinese Medicine (黑龍江中醫學院) (currently known as Heilongjiang University of Chinese Medicine (黑龍江中醫藥大學)) in the PRC, majoring in Chinese medicine resources, in July 1995 and a master's degree in bioengineering from Jilin University (吉林大學) in the PRC in June 2006.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, January 5, 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.